AXITINIB
Manner of administration:Oral
Restriction (Streamlined authority code: 7433)
Indication: Stage IV clear cell variant renal cell carcinoma (RCC)
Treatment phase: Continuing treatment beyond 3 months
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 56 | # of repeats: 5 | DPMQ: $1,020.84 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Inlyta | |||||
Manner of administration:Oral
Restriction
Indication: Stage IV clear cell variant renal cell carcinoma (RCC)
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 56 | # of repeats: 2 | DPMQ: $1,020.84 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Inlyta | |||||